HER2-Amplified Colon Cancer: A Biomarker That Argues Against the Next Standard Drug
A biomarker discovered on progression happens to explain, mechanistically, why the drug that's usually next in line might not have worked anyway.
C.B., a 56-year-old man, has managed a commercial fishing crew out of the same harbor for twenty-two years, and kept working through most of his first six months of chemotherapy — "the boat doesn't run itself," he told his oncologist more than once. His metastatic, RAS/BRAF wild-type left-sided colon cancer was diagnosed ten months ago with liver-only disease, and he completed eight months of FOLFOX plus bevacizumab with an initial partial response before this month's scan showed unambiguous growth in two liver lesions and a new small lesion not previously seen. Broader molecular profiling sent at progression, standard practice at this point in treatment, returned HER2 amplification — a finding not present, or at least not tested for, at original diagnosis.
For a RAS-wild-type patient progressing after first-line oxaliplatin-based therapy, the conventional next step is a switch to irinotecan-based chemotherapy with an anti-EGFR antibody such as cetuximab, which is precisely the population where anti-EGFR therapy has its strongest evidence. But HER2 amplification is not simply an alternative target sitting alongside that option — it is one of the specifically documented molecular mechanisms by which colorectal tumors acquire resistance to anti-EGFR therapy, bypassing EGFR blockade through a parallel signaling route. Tucatinib plus trastuzumab, validated in MOUNTAINEER for HER2-amplified, RAS-wild-type metastatic colorectal cancer with a real objective response rate and durable progression-free survival, offers a mechanistically coherent alternative — but the practical question in front of the team is whether a biomarker that predicts anti-EGFR resistance should be read as a reason to skip that option, or whether the evidence for doing so is still thinner than the confidence with which it gets stated in conversation. Two facts about C.B. specifically bear on that: he has never received an anti-EGFR antibody, so nothing in his history has selected for the resistance the biomarker predicts, and the amplification was not tested for at diagnosis, so nobody can say whether it is newly acquired or was there all along. The mechanism is well described; whether it describes his tumor's behavior is an inference, and worth naming as one.
Second-line treatment planning visit
Standard second-line therapy for RAS-wild-type disease progressing on oxaliplatin-based chemotherapy is FOLFIRI plus cetuximab — it's the best-validated option we have, with a large evidence base behind it. The HER2-resistance association is real biology, but I want to be careful about skipping a proven regimen based on a mechanistic argument rather than a trial that actually randomized patients like C.B. between the two strategies.
I'd push back gently on calling this a loose mechanistic argument. HER2 amplification as a bypass-track resistance mechanism to EGFR blockade is specifically described and replicated literature, not a single correlative study — the tumor has, in effect, already built a workaround for the pathway cetuximab blocks. MOUNTAINEER (Strickler et al., Lancet Oncology 2023) gives us a prospective option that targets the actual amplified driver instead. Giving cetuximab here isn't neutral — it's giving a drug against a target the tumor's own biology suggests it has already escaped.
I'd stop short of calling this proven inefficacy — no trial has randomized HER2- amplified patients specifically between the two regimens — but the mechanism is stronger than "a correlation."
There's a sequencing argument that doesn't require either of you to be fully right. If we start tucatinib and trastuzumab now and it fails, cetuximab is still fully available afterward, untested and uncompromised. If we start cetuximab first and it fails, we may have simply confirmed what the biomarker already predicted, without learning anything new — and we'll have spent a treatment line doing it. Starting with the HER2-targeted option preserves more real information either way.
Agreed: tucatinib plus trastuzumab as second-line therapy, with cetuximab- based chemotherapy preserved explicitly as the next planned line rather than abandoned, and baseline cardiac function confirmed normal before starting given trastuzumab's own monitoring requirements.
Not settled as a general rule: the medical oncologist's caution about extrapolating from mechanistic resistance data without a head-to-head trial was recorded as a real, open limitation of today's decision, not resolved by the sequencing argument that ultimately carried the room — the team was explicit that this reflects C.B.'s own tumor biology, not a claim that HER2 status should always override standard second-line sequencing.